C. Brewin, B. Andrews, and J. Valentine, Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults., Journal of Consulting and Clinical Psychology, vol.68, issue.5, pp.748-766, 2000.
DOI : 10.1037/0022-006X.68.5.748

. Invs, Conséquences sanitaires de la catastrophe AZF. http://www.invs.sante.fr/Dossiers-thematiques/Environnement-et-sante/Consequences-sanitaires-de-lacatastrophe-d-AZF (dernière consultation, 2014.

E. Foa, Psychosocial treatment of posttraumatic stress disorder, J Clin Psychiatry, vol.61, issue.5, pp.43-48, 2000.

F. Martenyi, E. B. Brown, H. Zhang, A. Prakash, and S. C. Koke, Fluoxetine Versus Placebo in Posttraumatic Stress Disorder, The Journal of Clinical Psychiatry, vol.63, issue.3, pp.199-206, 2002.
DOI : 10.4088/JCP.v63n0305

R. Kessler, S. Heeringa, M. Lakoma, M. Petukhova, A. Rupp et al., Individual and Societal Effects of Mental Disorders on Earnings in the United States: Results From the National Comorbidity Survey Replication, American Journal of Psychiatry, vol.165, issue.6, pp.703-711, 2008.
DOI : 10.1176/appi.ajp.2008.08010126

D. Regier, J. Myers, and M. Kramer, The NIMH Epidemiologic Catchment Area Program, Archives of General Psychiatry, vol.41, issue.10, 1984.
DOI : 10.1001/archpsyc.1984.01790210016003

R. Kessler, K. Mcgonagle, and S. Zhao, Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United States, Archives of General Psychiatry, vol.51, issue.1, pp.8-19, 1994.
DOI : 10.1001/archpsyc.1994.03950010008002

R. Kessler, W. Chiu, and O. Demler, Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication, Archives of General Psychiatry, vol.62, issue.6, pp.617-627, 2005.
DOI : 10.1001/archpsyc.62.6.617

D. Hirshfeld-becker, J. Micco, N. Simoes, and A. Henin, High risk studies and developmental antecedents of anxiety disorders, American Journal of Medical Genetics Part C: Seminars in Medical Genetics, vol.117, issue.2, pp.99-117, 2008.
DOI : 10.1002/ajmg.c.30170

W. Yates, Phenomenology and epidemiology of panic disorder, Ann Clin Psychiatry. juin, vol.21, issue.322, pp.95-102, 2009.

S. Bruce, K. Yonkers, M. Otto, J. Eisen, R. Weisberg et al., Influence of Psychiatric Comorbidity on Recovery and Recurrence in Generalized Anxiety Disorder, Social Phobia, and Panic Disorder: A 12-Year Prospective Study, American Journal of Psychiatry, vol.162, issue.6, pp.1179-87, 2005.
DOI : 10.1176/appi.ajp.162.6.1179

. Ansm, Bon usage des médicaments dans le traitement des troubles dépressifs et des troubles anxieux de l'adulte ? argumentaire, 2006.

. Vidal-recos, La prise en charge du trouble de panique

J. Ballenger, D. Wheadon, M. Steiner, W. Bushnell, and I. Gergel, Double-Blind, Fixed-Dose, Placebo-Controlled Study of Paroxetine in the Treatment of Panic Disorder, American Journal of Psychiatry, vol.155, issue.1, pp.36-42, 1998.
DOI : 10.1176/ajp.155.1.36

Y. Lecrubier, A. Bakker, G. Dunbar, and R. Judge, A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder, Acta Psychiatrica Scandinavica, vol.26, issue.2, pp.145-52, 1997.
DOI : 10.1097/00004714-198710000-00007

D. George, D. Nutt, R. Rawlings, M. Phillips, M. Eckardt et al., Behavioral and endocrine responses to clomipramine in panic disorder patients with or without alcoholism, Biological Psychiatry, vol.37, issue.2, pp.112-121, 1997.
DOI : 10.1016/0006-3223(94)00156-W

F. Graeff, F. Guimarães, D. Andrade, T. Deakin, and J. , Role of 5-HT in stress, anxiety, and depression, Pharmacology Biochemistry and Behavior, vol.54, issue.1, pp.129-170, 1996.
DOI : 10.1016/0091-3057(95)02135-3

P. Johnson, S. Lightman, and C. Lowry, A Functional Subset of Serotonergic Neurons in the Rat Ventrolateral Periaqueductal Gray Implicated in the Inhibition of Sympathoexcitation and Panic, Annals of the New York Academy of Sciences, vol.113, issue.1, 2004.
DOI : 10.1196/annals.1296.006

R. Lanzenberger, M. Mitterhauser, C. Spindelegger, W. Wadsak, N. Klein et al., Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder, Biological Psychiatry, vol.61, issue.9, pp.1081-1090, 2007.
DOI : 10.1016/j.biopsych.2006.05.022

K. Hamazaki, M. Itomura, M. Huan, H. Nishizawa, S. Sawazaki et al., Effect of ??-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial, Nutrition, vol.21, issue.6, pp.705-715, 2005.
DOI : 10.1016/j.nut.2004.07.020

D. Rudin, The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra, Biol Psychiatry, vol.16, issue.759, pp.837-50, 1981.

L. Fromm, D. Heath, R. Vink, and A. Nimmo, Magnesium Attenuates Post-Traumatic Depression/Anxiety Following Diffuse Traumatic Brain Injury in Rats, Journal of the American College of Nutrition, vol.47, issue.5, pp.529-533, 2004.
DOI : 10.1080/07315724.2004.10719396

S. Hercberg, P. Galan, P. Preziosi, S. Bertrais, L. Mennen et al., The SU.VI.MAX Study, Archives of Internal Medicine, vol.164, issue.21, pp.2335-2377, 2004.
DOI : 10.1001/archinte.164.21.2335

URL : https://hal.archives-ouvertes.fr/hal-01346671

R. D. Williams, INDUCED THIAMINE (VITAMIN B1) DEFICIENCY IN MAN, Archives of Internal Medicine, vol.71, issue.1, pp.38-53, 1983.
DOI : 10.1001/archinte.1943.00210010044003

S. Gilbody, T. Lightfoot, and T. Sheldon, Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity, Journal of Epidemiology & Community Health, vol.61, issue.7, pp.631-638, 2007.
DOI : 10.1136/jech.2006.050385

A. Coppen and C. Bolander-gouaille, Treatment of depression: time to consider folic acid and vitamin B12, Journal of Psychopharmacology, vol.19, issue.1, pp.59-65, 2005.
DOI : 10.1177/0269881105048899

M. Taylor, S. Carney, G. Goodwin, and J. Geddes, Folate for Depressive Disorders: Systematic Review and Meta-Analysis of Randomized Controlled Trials, Journal of Psychopharmacology, vol.18, issue.2, pp.251-257, 2004.
DOI : 10.1177/0269881104042630

L. Vitamine and B. Http, (dernière consultation : janvier 2015) (91) Le tryptophane http://a54.idata.over-blog, 2015.

D. Benton and R. Cook, The impact of selenium supplementation on mood, Biological Psychiatry, vol.29, issue.11, pp.1092-1100, 1991.
DOI : 10.1016/0006-3223(91)90251-G

W. Miller, Rollnick S., l'entretien motivationnel : aider la personne à engager le changement

. Oms, Therapeutic patient education

J. Desmeules, Syndrome sérotoninergique et interactions médicamenteuses, Pharma- Flash, pp.15-20, 2006.

. Manger-bouger, Allégations nutritionnelles http://www.mangerbouger.fr/bien-manger/infos-nutritionnelles/allegations-nutritionnelles-sur-lesproduits .html (dernière consultation, 2015.

J. Hellhammer, T. Hero, N. Franz, C. Contreras, and M. Schubert, Omega-3 fatty acids administered in phosphatidylserine improved certain aspects of high chronic stress in men, Nutrition Research, vol.32, issue.4, pp.241-50, 2012.
DOI : 10.1016/j.nutres.2012.03.003

A. Mclean, J. Rubinsztein, T. Robbins, and B. Sahakian, The effects of tyrosine depletion in normal healthy volunteers: implications for unipolar depression, Psychopharmacology, vol.171, issue.3, pp.286-97, 2004.
DOI : 10.1007/s00213-003-1586-8

-. Source, oméga 3 » : si la teneur en acide alpha-linolénique (ALA) est supérieure ou égale à 0,3 g pour 100 g, 100 ml ou 100 kcal ou si la teneur en acide docosahexaénoïque (DHA) est supérieure ou égale à 0,018 g pour 100 g, 100 ml ou 100 kcal